CD230抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD230 mouse mAb (green) and negative control (red).    

  
  

CD230. also known as the prion protein (PrP), is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein encoded by the PRNP gene. Normally expressed in neurons and other tissues, its physiological role remains debated but may involve copper binding, neuroprotection, and cellular signaling. Pathologically, CD230 is linked to prion diseases—a group of fatal neurodegenerative disorders (e.g., Creutzfeldt-Jakob disease, scrapie, bovine spongiform encephalopathy) caused by the misfolding of cellular prion protein (PrPᴼ) into a pathogenic isoform (PrPˢᶜ). This β-sheet-rich aggregate propagates by inducing conformational changes in normal PrPᴼ, leading to neuronal loss and spongiform brain damage.

CD230 antibodies are critical tools for studying prion biology and disease mechanisms. They distinguish between PrPᴼ and PrPˢᶜ, detect post-translational modifications (e.g., glycosylation), and map structural epitopes altered during misfolding. In diagnostics, these antibodies enable immunohistochemical detection of PrPˢᶜ in brain tissue or CSF biomarkers. Therapeutic applications are being explored, including antibody-mediated inhibition of PrPᴼ conversion or clearance of PrPˢᶜ aggregates. However, challenges persist due to PrPˢᶜ's resistance to degradation and the blood-brain barrier's limitations. Research continues to optimize CD230 antibody specificity and efficacy for both mechanistic insights and clinical translation.